Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus  by Santos, Elaine Cristina Lima dos et al.
r e v b r a s r e u m a t o l . 2 0 1 6;5 6(6):521–529
REVISTA BRASILEIRA DE
REUMATOLOGIA
O
P
g
e
E
J
a
b
a
A
R
A
A
K
S
N
G
A
C
P
L
N
P
F
F
h
2
lwww.reumato logia .com.br
riginal article
olymorphisms  in  NAT2  (N-acetyltransferase  2)
ene in patients  with  systemic  lupus
rythematosus
laine Cristina Lima dos Santosa, Amanda Chaves Pintoa, Evandro Mendes Klumbb,
acyara  Maria Brito Macedoa,∗
Universidade do Estado do Rio de Janeiro (UERJ), Departamento de Bioquímica, Rio de Janeiro, RJ, Brazil
Universidade do Estado do Rio de Janeiro (UERJ), Disciplina de Reumatologia, Rio de Janeiro, RJ, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 10 June 2015
ccepted 23 July 2016
vailable online 25 October 2016
eywords:
ystemic lupus erythematosus
-acetyltransferase 2
enetic polymorphism
cetylator phenotype
linical phenotypes
a  b  s  t  r  a  c  t
Objective: To investigate potential associations of four substitutions in NAT2 gene and of
acetylator phenotype of NAT2 with systemic lupus erythematosus (SLE) and clinical phen-
otypes.
Methods: Molecular analysis of 481C>T, 590G>A, 857G>A, and 191G>A substitutions in
the  NAT2 gene was performed by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) technique, from DNA extracted from peripheral blood samples
obtained from patients with SLE (n = 91) and controls (n = 97).
Results and conclusions: The 857GA genotype was more prevalent among nonwhite SLE
patients (OR = 4.01, 95% CI = 1.18–13.59). The 481T allele showed a positive association with
hematological disorders that involve autoimmune mechanisms, speciﬁcally autoimmune
hemolytic anemia or autoimmune thrombocytopenia (OR = 1.97; 95% CI = 1.01–3.81).
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Polimorﬁsmos  no  gene  NAT2  (N-acetiltransferase  2)  em  pacientes
com  lúpus  eritematoso  sistêmico
alavras-chave:
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Objetivo: Investigar potenciais associac¸ões de quatro substituic¸ões do gene NAT2 (N-
úpus eritematoso sistêmico
-acetiltransferase 2
olimorﬁsmo genético
enótipo acetilador
enótipos clínicos
acetiltransferase 2) e do fenótipo acetilador de NAT2 com o lúpus eritematoso sistêmico
(LES)  e os fenótipos clínicos.
Métodos: A análise molecular das substituic¸ões 481C>T, 590G>A, 857G>A e 191G>A do gene
NAT2 foi feita com a técnica de PCR-RFLP, usando DNA extraído de amostras de sangue
periférico obtidas de pacientes com LES (n = 91) e controles (n = 97).
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icenses/by-nc-nd/4.0/).
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Resultados e conclusões: O genótipo 857GA foi mais prevalente entre pacientes com LES não
brancas (OR = 4,01, IC 95% = 1,18-13,59). O alelo 481 T apresentou associac¸ão positiva com as
alterac¸ões hematológicas que envolvem mecanismos autoimunes, especiﬁcamente anemia
hemolítica autoimune ou trombocitopenia autoimune (OR = 1,97; IC 95% = 1,01-3,81).
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Systemic lupus erythematosus (SLE) is an autoimmune,
chronic and systemic syndrome. The involvement of various
tissues and organs is the result of chronic inﬂammatory pro-
cesses generated by the deposition of immune complexes,
resulting from an increased production of autoantibodies.
Although the etiology of SLE is not fully understood, studies
point to a complex interplay between genetic and environ-
mental determinants.1 Ultraviolet radiation, drugs, infectious
agents, smoking, and various chemical agents have been
described as potential risk factors for this disease.2 Studies in
different populations have shown that smoking habits have
a positive association with SLE, with odds ratios between 1.6
and 6.6.2–7 In addition to inﬂuencing the development of SLE,
the smoking habit has also been linked to the maintenance
of disease activity and to a lower response to treatment with
antimalarial drugs.4,8
The association between genetic factors and lupus, espe-
cially hydralazine-induced lupus, was ﬁrst assessed in 1970.
A relationship between N-acetyltransferase 2 enzyme (NAT2),
capable of acetylating the drug, and lupus was observed, with
a greater proportion of slow acetylator phenotype among
patients with the disease.9 A lower cumulative dose of pro-
cainamide was also able to induce lupus in patients with slow
acetylator phenotype when compared to patients with fast
acetylator phenotype.10 In another study, in which the smok-
ing habit and the phenotype of NAT2 enzyme, involved in
the acetylation of cigarette smoke components, were consid-
ered, the higher risk (2.26 times) developing of SLE attributed
to smokers versus nonsmokers was even higher (6.44 times)
when the slow phenotype of NAT2 enzyme was observed.2
The N-acetyltransferase enzymes (NATs) participate in
the second phase of metabolism of xenobiotics, and the
acetylation reaction can occur by two distinct pathways: by
O-acetylation, after the action of the ﬁrst-phase enzyme P450
(CYP450), and by N-acetylation, when the enzyme acts on the
compound in a previous step to the action of CYP450. Both
pathways may result in the formation of a DNA adduct.11
There are two isoforms of human N-acetyltransferase
enzymes, NAT1 and NAT2, which are differently expressed
according to the tissue and have speciﬁcity for differ-
ent substrates.11–13 Acetylation of aromatic compounds and
heterocyclic amines, such as 4-aminobiphenyl, present in
cigarette smoke,14 through the transfer of acetyl group of a
molecule of acetyl-CoA to the free-amino group of the com-
pound, is preferably promoted by NAT2.14The NAT2 isoform is encoded by the NAT2 gene, which
is located on chromosome 8 (8p22), together with the NAT1
gene and the pseudogene NATP. The NAT2 gene is highlyBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
polymorphic and the diversity of the described alleles results
from the combination of point mutations of selected bases
(SNPs – single nucleotide polymorphisms).15 The phenotype
of the enzyme can be determined by existing SNPs in the
coding region of the gene, which inﬂuences the afﬁnity for
the substrate, the catalytic activity and/or stability of the
resulting protein.16 Among the nucleotide changes commonly
used in order to infer the acetylator phenotype of NAT2,
481C>T (rs1799929), 590G>A (rs1799930), 857G>A (rs1799931),
and 191G>A (rs1801279) stand out.2,17,18
Due to the importance of the topic in question and the lack
of Brazilian research, in this study we performed an evalua-
tion of the presence of four substitutions in the NAT2 gene
(481C>T, 590G>A, 857G>A and 191G>A) and the phenotype of
NAT2 enzyme in patients with systemic lupus erythematosus
residents in the city of Rio de Janeiro. Our study population
was stratiﬁed according to smoking status and ethnic charac-
teristics. Some clinical features of the disease were also taken
into account in our analysis.
Materials  and  methods
Study  population
The study population was selected from a group of women
participating in a previous study, which sequentially included
SLE patients (according to the American College of Rheuma-
tology classiﬁcation criteria), regularly followed in the
Rheumatology Unit, UERJ, and women without lupus who had
attended for routine gynecological care in the same university
(UERJ).19,20
Clinical and socio-demographic aspects, including infor-
mation on race/ethnicity of the female participant and
of their parents, by self-declaration, and smoking habits
were obtained by applying a semi-structured questionnaire.
Patients and controls were classiﬁed as white-colored sub-
jects when the individual and his parents were white-colored
by self-declaration, and as nonwhite-colored if the individual
and/or at least one of her parents was brown- or black-colored
by self-declaration. Speciﬁc clinical data were obtained from
medical chart review.
The project was approved by the Research Ethics Commit-
tee of HUPE/UERJ (HUPE/UERJ #321 and #909), and all patients
were included only after signing an informed consent form
previously approved.
Molecular  analysis  of  polymorphisms  in  NAT2Genomic DNA was extracted from peripheral blood samples,
according to Vargas-Torres et al.21 Analysis of the substitutions
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analysis can be seen in Fig. 1.
The control group followed the Hardy–Weinberg principle
with respect to the analyzed substitutions (Table 2). The
genotype and allele distributions corresponding to the four
Table 1 – Clinical characteristics of patients with
systemic lupus erythematosus included in this study.
Clinical data
Age at onset of symptoms (mean ± SD) (years) 27.8 ± 10.9
Elapsed time between onset of symptoms and
diagnosis of SLE (mean ± SD) (months)
20.0  ± 28.3
American College of Rheumatology (ACR) criteria (%)
Malar rash 78.0
Discoid lesions 15.4
Photosensitivity 72.5
Oral ulcers 53.8
Arthritis 84.6
Pleuritis 33.0
Pericarditis 28.6
Hematological abnormalitiesa 39.6
Hemolytic anemia 44.6
Psychosis 14.3
Seizures 5.5
Renal impairment (proteinuria) 78.0r e v b r a s r e u m a t o l
81C>T, 590G>A, 857G>A and 191G>A in the NAT2 gene
as carried out with the use of PCR-RFLP (Polymerase
hain Reaction-Restriction Fragment Length Polymorphism)
echnique, according to Huang et al.,17 with some modiﬁca-
ions. Ampliﬁcation of genomic DNA was performed using
he following primers: 5′-GGAACAAATTGGACTTGG-3′ and
′-TCTAGCATGAATCACTCTGC-3′ (Life Technologies®). After
mpliﬁcation, aliquots of PCR product were digested sepa-
ately with the restriction enzymes KpnI (481C>T) and BamHI
590G>A), followed by electrophoretic analysis in agarose
el, and with MspI (857G>A) and TaqI (191G>A), followed by
nalysis by polyacrylamide gel electrophoresis. After elec-
rophoresis, the gels were stained with ethidium bromide and
he products of digestion were visualized under UV light. To
valuate the reproducibility of the technique, 10% of samples
ere randomly selected and reevaluated.
henotypic  classiﬁcation
n this study, the bimodal classiﬁcation,17 in which inter-
ediate and fast phenotypes are grouped into a single
ategory, was used. Thus, the presence and absence of the
T allele (absence of the four NAT2 substitutions, 481C>T,
90G>A, 857G>A, and 191G>A) deﬁne the fast and slow phen-
types, respectively. In practice, samples lacking one of the
our changes, or samples heterozygous for only one of the
ubstitutions, were considered as having fast acetylator phen-
types. On the other hand, the homozygous samples in only
ne of the substitutions were classiﬁed as slow acetylator
henotype. The deﬁnition of phenotypes of samples having
wo or more  changes has been made considering all possible
ombinations of alleles and verifying their frequency in our
opulation, according to the haplotypes’ estimation analysis
arried out based on the frequencies of individual substitut-
ons, as described later. Combinations containing at least one
are haplotype with an estimated frequency <0.01 were con-
idered unlikely and were discarded.
The samples without a result for one of the four substitut-
ons analyzed whose missing genotype would not interfere in
he phenotype deﬁned by the other three substitutions were
ncluded in the study.
tatistical  analysis
tudent’s t-test was used to analyze the differences between
eans and standard deviations and was performed using the
raphPad Prism software version 6.05 (GraphPad Software,
nc., San Diego, CA).
The study population was tested for deviations from
ardy–Weinberg using the Chi-squared test (2), assuming a
egree of freedom = 1, with the use of SNPStats software (Insti-
ut Català d’Oncologia, Barcelona, Spain).22
The differences between genotype and allele frequencies
f groups of cases and controls were evaluated by the 2
est or Fisher’s exact test. The odds ratios (OR) and conﬁ-
ence intervals (95% CI) were determined in order to estimate
he magnitude of the association between NAT2 substitut-
ons with the presence of systemic lupus erythematosus,
sing, where possible, co-dominant, dominant, and recessive
enetic models. The most frequent allele and the homozygous 6;5 6(6):521–529 523
genotype of this allele were considered as references.
These tests were performed using GraphPad Prism ver-
sion 6.05 software (GraphPad Software, Inc., San Diego,
CA).
The analyses of interactions between genotypes or phen-
otypes of NAT2, smoking status, ethnic characteristics, and
diagnosis of SLE, potential associations between genotypes or
phenotypes of NAT2,  and several clinical features of SLE, as
well as the estimation of haplotypes from the frequencies of
genotypes corresponding to the four substitutions, were per-
formed using SNPStats software (Institut Català d’Oncologia,
Barcelona, Spain).22 p-Values <0.05 were considered signiﬁ-
cant.
Results
Our study population consisted of 188 participants, 91 SLE
patients (the case group) and 97 women without SLE (the
control group). The mean age (±standard deviation) of SLE
patients (40.6 ± 11.1 years; 20–69 years) and of controls
(36.9 ± 10.8 years; 17–66 years) at the time of inclusion in the
study was signiﬁcantly different (p = 0.0214). Although the dis-
tributions by age in both groups also have been shown to be
different (p = 0. 0168), approximately 60% of women belonging
to the two groups were aged between 30 and 49 years. The per-
centages of non-white women were different between the two
study groups, with a marginal p-value (p = 0.0539). The most
important clinical features observed in patients with SLE are
shown in Table 1.
A total of 188 samples of DNA, corresponding to our study
population, were assessed with respect to the four NAT2
substitutions. The digestion proﬁles representative of eachANA, positive 60.4
a Reductions of platelets, lymphocytes and leukocytes were
grouped as hematological changes.
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Fig. 1 – Molecular analysis of four substitutions in the NAT2 gene. (A) Photograph of a 2.0% agarose gel stained with
ethidium bromide for analysis of the substitution 481C>T. Lane 1 – negative control of the digestion reaction (intact
amplicon); Lane 2 – representative sample of the NAT2 genotype 481CC (two alleles with KpnI restriction site); Lane 3 –
representative sample of the NAT2 genotype 481CT (only one of the alleles with KpnI restriction site); Lane 4 – representative
sample of the NAT2 genotype 481TT (two alleles without KpnI restriction site); Lane 5 – molecular weight pattern
(GeneRulerTM 100 bp DNA Ladder, ready to use – Fermentas). (B) Photograph of a 6.0% polyacrylamide gel stained with
ethidium bromide for analysis of the 590G>A substitution. Lane 1 – negative reaction control (intact amplicon); Lane 2 –
representative sample of the NAT2 genotype 590GG (two alleles with an additional TaqI restriction site); Lane 3 –
representative sample of the NAT2 genotype 590GA (only one of the alleles with an additional TaqI restriction site); Lane 4 –
representative sample of the NAT2 genotype 590AA (two alleles without an additional TaqI restriction site); Lane 5 –
molecular weight pattern (GeneRulerTM 100 bp DNA Ladder, ready to use – Fermentas). (C) Photograph of a 1% agarose gel
stained with ethidium bromide for analysis of the 857G>A substitution. Lane 1 – negative control of digestion reaction
(intact amplicon); Lanes 2 and 5 – representative samples of the NAT2 genotype 857GG (two alleles with an additional BamHI
restriction site); Lanes 3 and 4 – representative samples of the NAT2 genotype 857GA (only one allele with an additional
BamHI restriction site); Lane 6 – molecular weight pattern (GeneRulerTM 100 bp DNA ladder, ready to use – Fermentas). (D)
Photograph of a 5% polyacrylamide gel stained with ethidium bromide for analysis of the 191G>A substitution. Lane 1 –
representative sample of the NAT2 genotype 191GA (only one of the alleles with a Mspl restriction site); Lanes 2 and 3 –
representative samples of the NAT2 genotype 191GG (two alleles of an additional MspI restriction site); Lane 4 – negative
control for digestion reaction (intact amplicon); Lane 5 – molecular weight pattern (GeneRulerTM 1 kp DNA Ladder, ready to
use – Fermentas).
substitutions of the NAT2 gene, as well as the phenotype
distributions of NAT2 (Table 2) and haplotype frequencies
(Table 3) showed no statistically signiﬁcant differences
between cases and controls.
The study population was divided according to ethnic char-
acteristics in two subgroups, white and nonwhite subjects.
There was no signiﬁcant difference in the analysis related to
481C>T, 590G>A, and 191G>A substitutions, or to the pheno-
type of NAT2. However, with regard to the 857G>A substitution,
the GA genotype was more  prevalent in patients with SLEcompared to controls, but only among non-white participants
(OR = 4.01, 95% CI = 1.18–13.59; p = 0.023) (Table 4).
The study population was further stratiﬁed according to
smoking status (smokers or former smokers, and nonsmok-
ers), and no association of this variable was found, along with
NAT2 genotypes or the acetylator phenotype of the enzyme,
with the diagnosis of disease (data not shown).
The analyses above mentioned were performed only
in patients with lupus, considering the following clini-
cal characteristics: the presence of malar rash, discoid
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Table 2 – Genotype and allele distributions for each of the four substitutions of the NAT2 gene and acetylator phenotype
in case- (patients with SLE) and control groups.
Substitution/acetylator phenotype Genotype/allele/phenotype Cases (n = 91) Controlsa (n = 97) Cases vs. controls
n (%) or (f) n (%) or (f) OR (95% CI)
NAT2 481C>T CC  40 (44) 34  (35) 1.00
CT 39 (43) 46 (48) 0.72 (0.39–1.35)
TT 12 (13) 16 (17) 0.64 (0.27–1.53)
CT+TT 51 (56) 62 (65) 0.70 (0.39–1.26)
C 119 (0.65) 114 (0.59) 1.00
T 63 (0.35) 78 (0.41) 0.77 (0.51–1.18)
NAT2 590G>A GG  53 (59) 66 (68) 1.00
GA 32 (36) 27 (28) 1.48 (0.79–2.76)
AA 5 (6) 4 (4) 1.56 (0.40–6.09)
GA+AA 37 (41) 31 (32) 1.49 (0.82–2.71)
G 138 (0.77) 159 (0.82) 1.00
A 42 (0.23) 35 (0.18) 1.38 (0.84–2.29)
NAT2 857G>A GG  70 (84) 88 (93) 1.00
GA 13 (16) 7 (7) 2.34 (0.88–6.17)
AA 0 0 N/A
GA+AA 13 (16) 7  (7) 2.34 (0.88–6.17)
G 153 (0.92) 183 (0.96) 1.00
A 13 (0.08) 7 (0.04) 2.22 (0.86–5.71)
NAT2 191G>A GG  87 (96) 81 (91) 1.00
GA 4 (4) 7 (8) 0.53 (0.15–1.89)
AA 0 1 (1) N/A
GA+AA 4 (4) 8 (9) 0.47 (0.14–1.61)
G 178 (0.98) 169 (0.95) 1.00
A 4 (0.02) 9 (0.05) 0.42 (0.13–1.40)
Phenotype Fast 45 (53) 48 (53) 1.00
Slow 40 (47) 43 (47) 1.00 (0.56–1.82)
n, number of patients; f, allele frequency; N/A, not applicable.
The total samples with data relating to the four NAT2 polymorphisms and to the acetylator phenotype may differ from the total of analyzed
samples, due to the existence of unsatisfactory results.
a Hardy–Weinberg equilibrium test: NAT2 481C>T (p = 1.00); NAT2 590G>A (p = 0.50); NAT2 857G>A (p = 1.00); NAT2 191G>A (p = 0.19) (SNPStats).
Table 3 – Distributions of haplotypes of the NAT2 gene in groups of cases (lupus SLE patients) and controls.
Haplotype of NAT2 Cases (f) Controls (f) Cases vs. controls
481C>T 590G>A 857G>A 191G>A OR (95% CI)
T G G G 0.3231 0.3990 1.00
C G G G 0.3595 0.3405 1.25 (0.76–2.06)
C A G G 0.2170 0.1653 1.67 (0.94–2.95)
C G A G 0.0476 0.0360 1.89 (0.61–5.88)
C G G A 0.0139 0.0435 0.63 (0.18–2.12)
T G A G 0.0231 0 N/A
l
p
t
i
w
m
t
C
t
cf, haplotype frequency; N/A, not applicable.
Haplotypes with frequency <0.01 were not considered.
esions, photosensitivity, oral ulcers, arthritis, pleuritis,
ericarditis, autoimmune hemolytic anemia, autoimmune
hrombocytopenia, psychosis, seizures, proteinuria, and pos-
tive ANA. The 481T allele was more  prevalent in patients
ith hematological disorders (autoimmune hemolytic ane-
ia  or autoimmune thrombocytopenia), when comparedo those who  did not show this feature (OR = 1.97; 95%
I = 1.02–3.82; p = 0.0477). There was no association between
he other NAT2 substitutions, or NAT2 phenotype, and
linical characteristics of the patients (data not shown).In the analysis that included the smoking habit, the
group of SLE patients was subdivided into current smok-
ers and non-smokers, including ex-smokers. In isolation,
the smoking habit was associated with lupus discoid
lesions (OR = 8.62, 95% CI = 2.40–30.96, p = 0.0011) and pro-
teinuria (OR = 0.17, CI 95% = 0.05–0.59; p = 0.0056). However,
the joint analysis of NAT2 genotypes, or of acetylator phe-
notype, and smoking habit showed no association with
the clinical characteristics of patients with SLE (data not
shown).
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Table 4 – Analysis of interaction between genotypes related to substitutions in the NAT2 gene or NAT2 phenotype
and ethnic origin, in case- (SLE patients) and control groups.
Substitution/acetylator
phenotype
Skin color/ethnicity Genotype/phenotype Cases n (%) Controls n (%) Cases vs. controls
OR (95% CI)
NAT2 481C>T White C/C  12 (36) 6  (27) 1.00
C/T 19 (58) 11 (50) 0.86 (0.25–2.95)
T/T 2 (6) 5 (23) 0.20 (0.03–1.35)
Nonwhite C/C 28 (48) 28 (38) 1.00
C/T 20 (35) 35 (47) 0.57 (0.27–1.22)
T/T 10 (17) 11 (15) 0.91 (0.33–2.48)
NAT2 590G>A White G/G  18 (55) 17 (77) 1.00
G/A 14 (42) 4 (18) 3.31 (0.91–12.06)
A/A 1 (3) 1 (5) 0.94 (0.05–16.34)
Nonwhite G/G 35 (61) 49 (65) 1.00
G/A 18 (32) 23 (31) 1.10 (0.52–2.33)
A/A 4 (7) 3 (4) 1.87 (0.39–8.87)
NAT2 857G>A White G/G  27 (90) 19 (86) 1.00
G/A 3 (10) 3 (14) 0.70 (0.13–3.87)
A/A 0 0 N/A
Nonwhite G/G 43 (81) 69 (95) 1.00
G/A 10 (19) 4  (5) 4.01 (1.18–13.59)a
A/A 0 0 N/A
NAT2 191G>A White G/G  32 (97) 20 (95) 1.00
G/A 1 (3) 1 (5) 0.62 (0.04–10.57)
A/A 0 0 NA
Nonwhite G/G 55 (95) 61 (90) 1.00
G/A 3 (5) 6 (9) 0.55 (0.13–2.32)
A/A 0 1 (1) N/A
Phenotype White Fast 17 (55) 11 (52) 1.00
Slow 14 (45) 11 (48) 1.21 (0.41–3.63)
Nonwhite Fast 28 (52) 37 (54) 1.00
Slow 26 (48) 32 (46) 0. 93 (0.46–1.90)
White, individual and the parents white-colored by self-declaration; Nonwhite, an individual and/or at least one of the parents brown or black-
colored by self-declaration; n, number of patients; N/A, not applicable.
Signiﬁcant result is in bold letters.
a Fisher’s test: p = 0.0230.
Discussion  and  conclusion
N-acetyltransferase 2 (NAT2) variants have been widely stud-
ied in order to assess its distribution among different ethnic
groups, which can also be related to the exposure to different
environmental factors; and its association with a wide range of
diseases, including those of autoimmune origin. In this paper,
we evaluate the possible existence of an association between
the 481C>T, 590G>A, 857G>A and 191G>A polymorphisms in
the NAT2 gene and systemic lupus erythematosus.
The studies of an association between NAT2 and SLE
described in the literature, in general, consider the acetylator
phenotype and not NAT2 polymorphisms in isolation. Tak-
ing into account that the substitutions here discussed may
interfere with the levels of gene expression through post-
transcriptional regulation mechanisms (481C>T), change the
stability of the enzyme (590G>A and 191G>A), or modify the
selectivity and catalytic activity (857G>A),16 an association
analysis was also performed with each of the substitutions
in isolation. However, our results showed an absence of an
association between the four NAT2 substitutions, or the NAT2
acetylator phenotype and the disease (Table 1). The estimate ofhaplotypes also showed no association with SLE (Table 2), even
though aiding in the phenotypic classiﬁcation of the samples,
as mentioned above. Recent studies have also used this feature
to infer NAT2 phenotypes based on genotyping data.23,24
The polymorphisms analyzed in NAT2 gene have distinct
allelic distributions among different populations. Sabbagh
et al. conducted a worldwide survey of the frequency of sev-
eral NAT2 polymorphisms and also of their phenotype.25 The
worldwide frequency distribution of polymorphisms in this
study is found in Table 5. The observed frequencies in the
control group are similar to those found on several conti-
nents. The allele NAT2 191A showed a frequency of 0.02, equal
to that observed in North America, while the frequency of
the allele 590A was similar to that observed in Africa (0.23
and 0.25, respectively). On the other hand, the alleles NAT2
481T (0.35) and NAT2 857A (0.08) had intermediate frequen-
cies compared to those found in Africa and North America.
The population of Rio de Janeiro, as well as the Brazilian
population in general, results from the mixture of different
ethnic groups, particularly African, European and Amerindi-
ans. Studies have shown that the population of Rio de Janeiro
has approximately 31% of ancestry markers characteristic of
Africans, 55% of Europeans and 14% of Amerindians.26 In
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Table 5 – Frequencies of less frequent alleles of NAT2 (481T, 590A, 857A, 191A) observed in various populations.
Populations Substitutions of NAT2
857G>A 481C>T 590G>A 191G>A
Africaa 0.04 0.30 0.25 0.09
Europea 0.03 0.44 0.27 0.01
Asiaa 0.12 0.18 0.27 0
Americaa 0.20 0.25 0.11 0.02
Oceaniaa 0.04 0.04 0.32  0
This studyb 0.08 0.35 0.23 0.02
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his same population, it was observed that white individuals,
hrough self-declaration, had 86% of European ancestry and
3% of African or Amerindian ancestry. On the other hand, the
atients self-declared as nonwhites, of brown or black color,
ad 24% and 49% of African ancestry and 67% and 43% of Euro-
ean ancestry, respectively.27 These data reveal the greater
egree of miscegenation present in those self-declared as of
rown and black color. The high degree of ethnic heterogene-
ty of our study population could explain the close, but not
dentical, values to those observed in other populations.
In the literature, there are reports on the association of
AT2 polymorphisms with various diseases, such as dif-
erent types of cancer,28 periodontitis,29 and autoimmune
iseases,3,30,31 who  adopt the smoking habit as an environ-
ental risk factor.29,32 An association between the acetylator
henotype of NAT2, smoking and SLE was already observed.2
owever, in the Brazilian population, there is no study on
he association of polymorphisms in NAT2 gene and/or of
cetylator phenotype with this disease, especially in smok-
rs. Although several authors consider that the exposure to
obacco components may constitute a “trigger” for the devel-
pment of SLE,2–7 we had access to information on smoking
abit during the collection of biological samples, and not at
he time of disease onset. Therefore, our study population was
ubdivided into two groups, according to the smoking habit, as
mokers or ex-smokers and nonsmokers. Our results showed
o association between these variables and the disease (data
ot shown). It is worth noting that, at the time a patient is diag-
osed, she receives guidance to abstain from smoking, which
ay have created a bias in the analysis. In fact, fewer smokers
nd former smokers were observed in the group of cases, a
act that was not related to a protection of smoking habits in
elation to disease development. It should be noted that addi-
ional smoking data, including exposure time and the number
f packs of cigarettes/day, at the ﬁrst indication of disease
anifestation, could contribute to the analysis carried out,
aking into account the possibility of the differential metabo-
ization of various components of cigarette smoke, depending
n the acetylator phenotype. However, the time of onset of the
isease is a complex aspect to be established. It is frequent the
ccurrence of a period of several months between the onset
f symptoms and disease diagnosis.
Besides the difference in the frequency of NAT2 polymor-
hisms in different populations, the incidence of SLE is higher
n ethnically mixed patients.5 Thus, in this study, we evaluated
hether there was an association between the distribution ofluded in the case group.
NAT2 polymorphisms and SLE patients with this ethnic fea-
ture. With this in mind, self-declarations and information on
the parent (father and mother) skin color were used to deﬁne
the ethnic origin of the patients, as reported in the literature,21
but we  acknowledge that other methods could be more  appro-
priate to this end. Signiﬁcant results were observed only in
relation to the NAT2 857G>A polymorphism, with the genotype
857GA representing a potential risk for the disease in non-
white women (Table 4). The NAT2 857G>A substitution has as
a consequence, in the protein, the change of the amino acid
glycine by glutamate (G286E). This change modiﬁes the access
to the active site of the enzyme, which results in reduced selec-
tivity and catalytic capacity.16 Therefore, the NAT2 857G>A
polymorphism is related to the reduction in the metabolism of
aromatic and heterocyclic amines.16 The substitution 857G>A
is present in 11 NAT2 alleles, two of which have a slow acety-
lator phenotype, and the other ones have not yet had their
phenotypes deﬁned.33 The slow acetylator phenotype could
confer an increased risk for SLE, since the body would remain
exposed for a longer time, for example, to components of
cigarette smoke. It is worth noting that the variables eth-
nic origin and NAT2 857G>A genotypes were not individually
associated with SLE. Nevertheless, the literature points to a
higher incidence of SLE in ethnically mixed individuals,1 and,
in a population of the city of Ilheus (Bahia/Brazil), the 857GA
genotype was more  prevalent in African-Brazilian subjects,
compared to whites and Amerindians.34 The ancestry of the
Rio de Janeiro population is similar to those estimated values
for the population of Brazilian Northeast.26,35 However, it has
been suggested that large urban centers, like Rio de Janeiro,
present more  diverse patterns of ethnic mixture.26
The organs affected and the intensity of clinical manifes-
tations in SLE patients characterize the severity of the disease
and somehow guide the therapeutic scheme selection. The
only signiﬁcant result in the analysis of the interaction of
the NAT2 polymorphisms or of the acetylator phenotype with
clinical features of SLE was the greater prevalence of the
allele 481T in patients with hematologic diseases, speciﬁcally
autoimmune hemolytic anemia or autoimmune thrombocy-
topenia (data not shown). The reduction of these cell types
may be associated with the immunosuppression caused by
the severity of the disease or by the use of immunomodula-
tory drugs.36 So far, there is no evidence as to the way the
genotypes containing the allele NAT2 481T can inﬂuence the
reduction of these blood cells, and this undoubtedly requires
further investigation.
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However, when considering only the smoking habit, we
found a correlation with the presence of discoid lupus
(OR = 8.62, 95% CI 2.40–30.96; p = 0.0011) and proteinuria
(OR = 0.17, 95% CI 0.05–0.59; p = 0.0056). In several studies,
dermatologic alterations present in patients with SLE were
associated with smoking and, as previously mentioned, the
treatment of these lesions in smokers seems to require higher
doses of antimalarials, compared to nonsmokers.37–39 In our
study, the small number of patients with SLE and smokers
(n = 7) did not allow us to infer if smoking habit really had an
impact on the pharmacological approach. The smoking habit
is also associated with renal disorders, such as proteinuria
and nephropathy40; however, in this study, from 71 patients
with proteinuria, only 7 are current smokers, 13 are former
smokers, and most were lifetime nonsmokers.
In the Brazilian population, there are few studies on geno-
type and allele distributions of NAT2, and there are no reports
about the association of NAT2 polymorphisms and SLE. We
believe that our work has a leading role in this area, and we
understand it as a formulator of the hypothesis of a poten-
tial role of NAT2 polymorphisms as a factor associated with
the disease in our country, and of a possible association with
speciﬁc clinical phenotypes. However, further studies involv-
ing larger populations are needed, to conﬁrm the association
between the NAT2 857G>A polymorphism and systemic lupus
erythematosus in self-declared non-white Brazilian women,
ideally including ethnic proﬁling with the use of ancestry
markers.
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